Also listed on Botulinum Toxin Research Associates, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Collateral for a security interest recorded Feb 7, 2025 (Hayfin Services LLP).
Term ends Aug 24, 2027 · High confidence
20-year base term ended Mar 8, 2024
Held by Revance Therapeutics, Inc.
Filed Mar 8, 2004 as application 10/793,964 · Granted Apr 8, 2014
Base term plus 1264 days of patent term adjustment (USPTO delay)
Today
2004
2027
Clock starts
Mar 8, 2004
Mar 8, 2004
Term ends
Aug 24, 2027
Aug 24, 2027
Granted
Apr 8, 2014
Apr 8, 2014
base term
patent term adjustment
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
1,264
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
This patent's term runs 1264 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 8, 2004, when this application, 10/793,964, was filed | Mar 8, 2024 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +1264 days, USPTO patent term adjustment record | Aug 24, 2027 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Aug 24, 2027 | High confidence |
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 6, 2004 Reel 15182, frame 270 | Borodic, Gary E.; Acquadro, Martin | Botulinum Toxin Research Associates, Inc. | Assignment of Assignor's Interest |
| Jun 29, 2004 Reel 14798, frame 944 | Borodic, Gary E.; Acquadro, Martin Andrew | Botulinum Toxin Research Assocates, Inc. | Assignment of Assignor's Interest |
| Jun 3, 2016 Reel 38870, frame 160 | Botulinum Toxin Research Associates, Inc. | Revance Therapeutics, Inc. | Assignment of Assignor's Interest |
| Mar 18, 2022 Reel 59437, frame 654 | Revance Therapeutics, Inc. | Athyrium Buffalo LP | Security Interest |
| Feb 7, 2025 Reel 70153, frame 630 | Athyrium Buffalo LP | Revance Therapeutics, Inc. | Release of Security Interest |
| Feb 7, 2025 Reel 70153, frame 663 | Revance Therapeutics, Inc.; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 7, 2025 Reel 70153, frame 736 | Revance Therapeutics, Inc.; Bellus Medical, LLC; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 17, 2025 Reel 70239, frame 739 | Revance Therapeutics, Inc. | Jpmorgan Chase Bank, N.a. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Aug 2027
Term ends Aug 24, 2027. No further fees fall due before then
Note
The 1264 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
36
later US patents cite this one
That is top 25% of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.